stockrow
Friday 6 November 2026
Export LGND’s income statement to Excel — free account
Ligand Pharmaceuticals Incorporated
LGND Healthcare Biotechnology
Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024.
- Revenue
- −31.8%
- EPS
- −123.8%
- Free cash flow
- −268.5%
- Total debt
- +153.3%
Quarter to September 2026, against a year earlier
306.43
7.43
+2.48%
Follow LGND
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
30.01 | 25.47 | 31.58 | 120.47 |
P/S ratio |
13.64 | 14.46 | 21.83 | 24.57 | |
P/FCF ratio |
60.02 | 29.50 | 44.23 | 59.85 | |
P/Operating CF |
79.63 | 81.53 | 264.04 | (226.00) | |
P/B ratio |
3.59 | 3.98 | 6.55 | 6.48 | |
Price to Tangible BV |
5.30 | 5.85 | 9.66 | 13.80 | |
EV/Sales |
12.77 | 13.49 | 21.25 | 27.55 | |
EV/EBITDA |
48.15 | 29.82 | 49.70 | 121.00 | |
EV/Operating CF |
69.35 | 29.98 | 46.88 | 76.82 | |
EV/FCF |
56.19 | 27.50 | 43.07 | 67.12 | |
Quick Ratio |
21.83 | 20.81 | 30.83 | 13.35 | |
Current Ratio |
22.23 | 21.28 | 31.18 | 13.35 | |
Net Debt/EBITDA |
(15.05) | (13.85) | (14.86) | (164.93) | |
Debt/Assets |
28.59% | 29.17% | 51.54% | 50.42% | |
Debt/Equity |
0.44 | 0.45 | 1.16 | 1.17 | |
Asset Turnover |
0.21 | 0.23 | 0.19 | 0.14 | |
Operating CF/Net income |
1.03 | (3.65) | 0.50 | 0.97 | |
Capex/Depreciation |
0.03 | 0.90 | (0.02) | 0.21 | |
Interest Coverage |
7.76 | 9.94 | 4.91 | (5.44) | |
Research and Development Expense of Revenue |
5.88% | 4.15% | 23.03% | 3.51% | |
Selling, General and Administrative Expense of Revenue |
41.95% | 40.28% | 45.72% | 92.22% | |
Intangible Assets out of Total Assets |
0.21 | 0.21 | 0.14 | 0.23 | |
Share Based Compensation of Revenue |
23.92% | 20.49% | 21.44% | 23.09% | |
Graham Net Nets |
0.08 | 0.08 | 0.04 | (0.12) | |
Graham Number |
86.35 | 94.06 | 104.22 | 53.02 | |
Earnings Yield |
3.33% | 3.93% | 3.17% | 0.83% | |
Free Cash Flow Yield |
1.67% | 3.39% | 2.26% | 1.67% | |
Revenue per Share |
3.09 | 2.60 | 3.17 | 3.94 | |
Operating CF per Share |
2.37 | 2.45 | 1.20 | (1.38) | |
Capex per Share |
0.01 | 0.34 | (0.01) | 0.13 | |
Free Cash Flow per Share |
2.38 | 2.79 | 1.19 | (1.26) | |
Cash per Share |
39.11 | 39.81 | 68.32 | 22.41 | |
Shareholders Equity per Share |
52.60 | 50.16 | 48.22 | 48.18 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
52.60 | 50.16 | 48.22 | 48.18 | |
Free Cash Flow |
46.12 | 55.44 | 23.87 | (25.09) | |
Working Capital |
794.82 | 824.75 | 1,410.38 | 490.86 | |
Capital Expenditures |
0.20 | 6.75 | (0.14) | 2.50 | |
Net Current Asset Value |
288.85 | 330.63 | 238.76 | (745.08) | |
EV/EBIT |
83.48 | 39.14 | 65.18 | 290.85 | |
Capex to Sales |
0.00 | (0.13) | 0.00 | (0.03) | |
Price to Operating Income |
89.17 | 41.97 | 66.94 | 259.34 | |
| Other line items | |||||
Average Receivables |
51.75 | 48.81 | 61.16 | 70.66 | |
Average Payables |
4.24 | 5.32 | 8.99 | 21.72 | |
Average Inventory |
11.62 | 13.94 | 12.88 | 13.20 | |
Average Assets |
1,251.21 | 1,218.77 | 1,567.24 | 1,857.12 | |
Average Common Equity |
923.83 | 896.43 | 898.02 | 955.97 |
Columns are period end dates · fundamentals updated 6 Nov 2026